Epidemiology


Etiology

Primary osteoporosis (most common)

  • Type I (postmenopausal osteoporosis): postmenopausal women
  • Type II (senile osteoporosis): gradual loss of bone mass as patients age (especially > 70 years)

Secondary osteoporosis

Additional risk factors

  • Cigarette smoking
  • Immobilization or inadequate physical activity
  • Malabsorption (e.g., celiac disease), malnutrition (e.g., diet low in calcium and vitamin D), anorexia

Pathophysiology


Clinical features


Diagnostics


Treatment

Bisphosphonates

  • Alendronate, Risedronate, Ibandronate, Zoledronic acid
  • Indications: preferred initial treatment in all patients
  • See Paget disease > Bisphosphonates for details

Nonbisphosphonates

Denosumab

  • Mechanism of action
    • Monoclonal antibody against the receptor activator of nuclear factor-κB ligand (RANKL)
    • Targets RANKL by mimicking osteoprotegerin → interference in osteoclast maturation → ↓ osteoclast activity
  • Teriparatide, Abaloparatide
  • Recombinant human parathyroid hormone that increases osteoblastic activity → increased bone growth
    • Pulsatile PTH secretion has an anabolic effect on bone metabolism, stimulating osteoblast proliferation, decreasing osteoblast apoptosis, and inducing increased formation of new bone.  Recombinant PTH analogues (eg, teriparatide) are used to treat severe osteoporosis; these analogues promote bone remodeling by inducing increased resorption of old bone while stimulating a corresponding increase in new bone production, resulting in a net increase in total bone mass (ie, positive bone balance).
    • Also increases gastrointestinal calcium absorption & renal tubular calcium reabsorption